Premature ovarian failure: long-term sequelae

Maclaran, Kate; Horner, E; Panay, Nick

doi:10.1258/mi.2010.010014

Cited by 51 publications

(47 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 It involves hypergonadotropic hypogonadism, increasing symptoms of estrogen deficiency and subfertility. To evaluate whether the mice treated with TPloaded nanoparticles were suitable as a POI animal model, serum AMH was measured because it is not influenced by the estrous cycle.…”

Section: Discussionmentioning

confidence: 99%

The potential of follicle-stimulating hormone peptide-modified triptolide-loaded nanoparticles to induce a mouse model of premature ovarian insufficiency

Chen¹,

Chen²,

Ma³

et al. 2015

IJN

View full text Add to dashboard Cite

The use of triptolide (TP) is limited by its poor water solubility and severe toxicity. In this study, we developed an active drug delivery system (TP-loaded nanoparticles) that could help improve the water solubility of TP and decrease its toxicity. Then, we investigated whether TP-loaded nanoparticles could be used to establish a novel premature ovarian insufficiency mouse model. The mice treated with TP-loaded nanoparticles for 35 days displayed normal growth, decreased serum antimullerian hormone, prominent ovarian fibrosis and vacuolar changes, fewer follicles and corpus lutea, increased collapsed oocytes and follicle apoptosis, and sterility. In conclusion, this model appears to show the reproductive characteristics associated with premature ovarian insufficiency in women and will allow us to study the mechanism of the effects of traditional Chinese medicine on gonadal toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

The potential of follicle-stimulating hormone peptide-modified triptolide-loaded nanoparticles to induce a mouse model of premature ovarian insufficiency

Chen¹,

Chen²,

Ma³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…In the developed world menopause under 45 years in classified as premature ovarian failure [8][9] . Women with premature ovarian insufficiency have an earlier onset of both CVD and osteoporosis.…”

Section: Effect Of Hrt Premature Ovarian Insufficiencymentioning

confidence: 99%

Latest Evidence on Using Hormone Replacement Therapy in the Menopause

Akter¹,

Shirin²

2018

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Hormone replacement therapy (HRT) is the most effective therapy of menopausal symptoms for perimenopausal and menopausal women. When HRT is individually tailored women gain maximum advantages and the risk are minimized. There are different types of hormones with different doses and different routes of delivery exist. . The use of HRT is an individual decision which women can only make once she has been given correct information and advice from healthcare professionals. HRT should be recommended in women with premature ovarian insufficiency with advice to continue until the average age of menopause at 51.4 years. This review item promotes confidence in prescribing HRT in most symptomatic women. Prescribing HRT in women with relative contraindication where evidence is limited. Quality of life is priority. Multidisciplinary approach may be necessary and informed written consent documented.

show abstract

“…Analysis of DEXA scans performed at diagnosis of POF show 3.6% of women have bone density within the osteoporotic range and 25.9% have osteopenia [11]. Oestrogen therapy is the most effective intervention for preventing bone loss in women with POF [11] and HRT, even low dose regimens, reduces the risk of osteoporosis and subsequent fractures [12,13]. Additional measures, including regular weight-bearing exercise, a calcium-rich diet with consideration of calcium and vitamin D supplementation if deficient, have also been shown to be beneficial.…”

Section: Osteoporosismentioning

confidence: 99%